1. Role of adiponectin in the relationship between visceral adiposity and fibroblast growth factor 23 in non-diabetic men with normal kidney function
- Author
-
Tomoaki Morioka, Yuko Yamazaki, Yoshinori Kakutani, Akinobu Ochi, Masaaki Inaba, Yasuo Imanishi, Yuka Natsuki, Masanori Emoto, Shinya Fukumoto, Tetsuo Shoji, Masafumi Kurajoh, and Katsuhito Mori
- Subjects
Adult ,Male ,Fibroblast growth factor 23 ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Population ,Renal function ,Disease ,Kidney ,urologic and male genital diseases ,Endocrinology ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,education ,Adiposity ,education.field_of_study ,Adiponectin ,business.industry ,medicine.disease ,Obesity ,Fibroblast Growth Factors ,Fibroblast Growth Factor-23 ,stomatognathic diseases ,Female ,Metabolic syndrome ,business - Abstract
Fibroblast growth factor 23 (FGF23) is a key regulator of phosphate metabolism. Circulating FGF23 levels are associated with obesity, metabolic syndrome, and cardiovascular disease in the general population, but the underlying mechanism remains unclear. Therefore, we aimed to determine the associations between serum FGF23 levels and visceral adiposity as well as serum adiponectin levels in 189 adults without diabetes and with normal kidney function who were selected from the MedCity21 health examination registry. The exclusion criteria included diabetes mellitus or impaired kidney function (estimated glomerular filtration rate [eGFR]
- Published
- 2022